Cherenkov imaging incorporating 3D surface imaging for TSET

切伦科夫成像结合表面成像用于TSET 摘要 临床证明全身皮肤电子放射治疗霉菌病有效 芬戈里德。然而，由于设置定位的不确定性和潜在的患者移动 全皮肤电子治疗(TSET)，给患者皮肤组织的剂量可能会偏离剂量 处方药。切伦科夫来自组织的发射最近被证明，提供了一种映射 与对皮肤组织的辐射传递有关。通过时间选通增强来最佳地捕获信号 摄像机，与线性加速器脉冲同步，允许拒绝大多数背景 房间照明，并提供高剂量率的每一次放射治疗的实时视频。这个 切伦科夫成像的实施提供了一种极好的技术来检测大脑中的异常 治疗，否则就不会被注意到。这项提议寻求将这项技术作为一种 通过临床试验验证工具，以监测TSET患者的日常治疗提供情况 制定可应用于采集信号的适当校正，以确保它是定量的 准确记录所提供的皮肤剂量。三个最主要的因素，它们改变了 剂量和切伦科夫信号之间的线性，是对透视方向、组织 曲率和组织光学属性。这些重要的修正在这项初步研究中被量化。 Tset，与开发切伦科夫成像的DoseOptics LLC公司合作 辐射核查技术，完善辐射传递的日常监测技术。我们 将通过比较活体9点的测量结果来比较切伦科夫成像的剂量学准确性 使用OSLD和闪烁体探测器的地点。此外，我们还将在光学系统中进行测量 TSE治疗条件下已知组织光学性质的模体和蒙特卡罗模拟 对三个修正因子进行了量化研究。我们还将开发覆盖皮肤剂量的技术 从校正的切伦科夫图像到基于表面3D的患者特定表面解剖 在TSE治疗前获得的身体轮廓数据，以评估每天的实际皮肤剂量分布 TSE治疗，并进行基于MC的剂量分布的综合比较 治疗计划系统。总而言之，该项目将在最引人注目的系统上取得进展 几十年来一直用于放射治疗成像。该项目的核心是组合技术系统、测试 TSET设置中的实用程序。

Cherenkov imaging incorporating surface imaging for TSET Abstract Whole-body skin electron radiotherapy has been clinically demonstrated to be effective to treat mycosis fungoides. However, due to setup positioning uncertainties and potential patient movements during total skin electron therapy (TSET), dose delivered to the patient skin tissue can deviate from dose prescription. Cherenkov emission from tissue has recently been demonstrated, providing a mapping related to the radiation delivery to skin tissue. The signal is optimally captured by time-gated intensified cameras, synchronized to the linear accelerator pulses, allowing rejection of the majority of background room light, and providing real time video of each radiotherapy treatment with high dose rates. The implementation of Cherenkov imaging offers an excellent technology to detect abnormalities in the treatment, which would otherwise go unnoticed. This proposal seeks to advance this technology as a verification tool through a clinical trial to monitor the daily treatment delivery of TSET patients and develop proper corrections that can be applied to the acquired signal to ensure it is quantitatively accurate in documenting delivered skin dose. Three of the most dominant factors, which alter the linearity between dose and Cherenkov signal, are the corrections for perspective direction, tissue curvature, and tissue optical properties. These important corrections are quantified in this pilot study of TSET, in partnership with DoseOptics LLC, the company that developed the Cherenkov imaging technology for radiation verification, to perfect technology for daily monitoring of radiation delivery. We will compare the dosimetry accuracy of Cherenkov imaging by comparing measurements in-vivo at 9 locations using OSLD and Scintillator detectors. In addition, we will perform measurements in optical phantoms of known tissue optical properties at TSE treatment conditions and Monte-Carlo simulation studies to quantity the three correction factors. We will also develop techniques to overlay skin dose obtained from corrected Cherenkov image to patient-specific surface anatomy based on surface 3D body contour data obtained before TSE treatment to assess the actual skin dose distribution for daily TSE treatment and perform a comprehensive comparison of dose distribution based on MC-based treatment planning system. Taking together, this project will advance on the most compelling systems for radiotherapy imaging in decades. The core of the project is combined technology systems, testing the utility in the setting of TSET.